Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study

BACKGROUND: Bladder cancer is the 10th most common cancer globally, with a growing incidence in Japan. Evaluation of molecular, genetic, and cellular biomarkers that predict treatment response and prognosis in patients with metastatic urothelial carcinoma (mUC) may help optimize sequential treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishiyama, Hiroyuki, Tsuzuki, Toyonori, Ohyama, Chikara, Matsuyama, Hideyasu, Shinozaki, Kenta, Hayashi, Yuko, Hayashi, Nobuya, Koto, Ryo, Shin, Eisei, Ogawa, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543076/
https://www.ncbi.nlm.nih.gov/pubmed/37498492
http://dx.doi.org/10.1007/s10147-023-02386-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543076/
https://www.ncbi.nlm.nih.gov/pubmed/37498492
http://dx.doi.org/10.1007/s10147-023-02386-y

Ejemplares similares